NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
CLARINEX-D 12 HOUR (desloratadine and pseudoephedrine sulfate) by Merck & Co. is histamine h1 receptor antagonists [moa]. Approved for histamine-1 receptor antagonist [epc]. First approved in 2006.
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLARINEX-D 12 HOUR is an oral extended-release combination tablet containing desloratadine (a selective H1-receptor antagonist) and pseudoephedrine sulfate (a decongestant). It treats allergic rhinitis symptoms including nasal congestion, sneezing, and itching by blocking histamine receptors and reducing nasal swelling. The dual mechanism provides both antihistamine and decongestant relief in a single 12-hour formulation.
$0.764MPart D
LOE ApproachingAging product with modest Medicare utilization (1,260 Part D claims in 2023) signals a small, potentially contracting commercial team managing market transition.
Mechanism of Action
Histamine H1 Receptor Antagonists
Pharmacologic Class:
Histamine-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Started Apr 2006
34 enrolled
Healthy
Career Relevance
Working on CLARINEX-D 12 HOUR offers limited career growth potential given its LOE-approaching status and minimal linked job openings. This role is best suited for early-career professionals seeking stability in a mature product environment or those focused on market access and generic transition management rather than brand-building innovation.
Brand Manager
Worked on CLARINEX-D 12 HOUR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.